ClinVar Miner

Submissions for variant NM_170707.4(LMNA):c.1444C>T (p.Arg482Trp) (rs57920071)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Genetic Services Laboratory,University of Chicago RCV000015579 SCV000247852 pathogenic Familial partial lipodystrophy 2 2014-11-14 criteria provided, single submitter clinical testing
Molecular Genetics Laboratory,London Health Sciences Centre RCV001174239 SCV001337368 pathogenic Charcot-Marie-Tooth disease criteria provided, single submitter clinical testing
Invitae RCV001235764 SCV001408468 pathogenic Charcot-Marie-Tooth disease, type 2 2019-11-12 criteria provided, single submitter clinical testing This sequence change replaces arginine with tryptophan at codon 482 of the LMNA protein (p.Arg482Trp). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and tryptophan. This variant is not present in population databases (ExAC no frequency). This variant has been observed in several individuals affected with familial partial lipodystrophy and was observed to segregate with disease in a family (PMID: 19622949, 25885670). ClinVar contains an entry for this variant (Variation ID: 14489). This variant has been reported to affect LMNA protein function (PMID: 19220582). This variant disrupts the p.Arg482 amino acid residue in LMNA. Other variant(s) that disrupt this residue (p.Arg482Gln) have been determined to be pathogenic (PMID: 10587585, 10999791, 19418082, 19859838, 20130076, 20625965, 26662654). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV001266075 SCV001444247 pathogenic Inborn genetic diseases 2018-12-10 criteria provided, single submitter clinical testing
OMIM RCV000015579 SCV000035844 pathogenic Familial partial lipodystrophy 2 2001-05-01 no assertion criteria provided literature only
Epithelial Biology; Institute of Medical Biology, Singapore RCV000057298 SCV000088411 not provided not provided no assertion provided not provided
Broad Institute Rare Disease Group,Broad Institute RCV001248961 SCV001422760 pathogenic Familial partial lipodystrophy 2020-01-22 no assertion criteria provided curation The p.Arg482Trp variant in LMNA has been reported in at least 12 European individuals with familial partial lipodystrophy, segregated with disease in at least 7 affected relatives from 2 families (PMID: 15531479, 10655060,11344241), and has been identified in 0.0009% (1/113640) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs57920071). This variant has also been reported in ClinVar as pathogenic (Variation ID: 14489). In vitro functional studies provide some evidence that the p.Arg482Trp variant may slightly impact protein function (PMID: 25524705). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. One additional likely pathogenic and one pathogenic variant, resulting in a different amino acid change at the same position, p.Arg482Leu and p.Arg482Gln, have been reported in association with disease in the literature and ClinVar, supporting that a change at this position may not be tolerated (PMID: 10655060, 14597414, 19201734, 23313286, 10587585, 20130076, 28492532 /Variation ID: 14490 and 14486). In summary, this variant meets criteria to be classified as pathogenic for familial partial lipodystrophy in an autosomal dominant manner based on cosegregation with disease in multiple affected families and the prevalence of this variant in many affected individuals. ACMG/AMP Criteria applied: PP1_strong, PS4_moderate, PM5, PM2, PP3, PS3_supporting (Richards 2015).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.